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Abstract
Purpose Cancer survivors are increasingly expected to
manage the consequences of cancer and its treatment for
themselves. There is evidence that self-efficacy is impor-
tant for successful self-management and that this can be
enhanced with support. The purpose of this study was to
assess self-efficacy to manage problems in the year following
primary treatment.
Methods This cross-sectional online survey included cancer
survivors who had completed their treatment within the past
12 months. Self-efficacy was assessed and variables expected
to be associated with self-efficacy were measured using
validated scales including quality of life, well-being, illness
perceptions, depression and social support.
Results One hundred eighty-two respondents (mean age 50;
81 % female) completed the survey. They had been treated for
a range of cancers; most commonly breast (45 %). Self-
efficacy scores varied between individuals and according to
the illness-related task to be managed. Respondents were least
confident in managing fatigue andmost confident in accessing
information about their cancer. Individuals most likely to
report low self-efficacy were women, those experiencing
higher levels of pain and/or depression, lower well-being
scores, lower socio-economic status, low levels of social
support, or a more negative perception of cancer.
Conclusions Self-efficacy to self-manage problems faced as a
consequence of cancer and its treatment can vary widely in the
year following treatment. Fatigue may be particularly difficult
to manage.
Implications for Cancer Survivors Variations in self-efficacy
highlight the importance of assessing specific problems faced
and people’s confidence to manage them in order to tailor
appropriate self-management support.
Keywords Self-management . Cancer survivors .
Self-efficacy . Confidence . Neoplasms
Introduction
By 2050, an estimated 70 million people will be living with a
diagnosis of cancer worldwide; an almost three-fold increase
since 2002 [1]. Rising survival rates are due to improvements
in detection and treatments, with many people faring well.
However, cancer and its treatment can have a considerable and
long-term impact on everyday life [2-4]. With an ageing
population and an aftercare system that is not meeting
people’s needs, there is growing concern about how best
to support cancer survivors and new models of aftercare
are being developed and evaluated [5-7].
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Self-management in cancer survivorship has been defined
as “awareness and active participation by the person in their
recovery, recuperation and rehabilitation, to minimise the
consequences of treatment, and promote survival, health and
well-being” [6]. This will involve managing consequences of
cancer and its treatment (physical, psychological, social, prac-
tical problems), understanding how and when to seek support,
recognising and reporting signs and symptoms of possible
disease progression and making lifestyle changes to promote
health, well-being and survival. People will be supported to
self-manage in a variety of ways but the onus will be on them
to initiate contact with healthcare professionals and others to
support them [6]. We do not yet understand how able people
feel to self-manage. Failure to provide appropriate support
could have serious consequences with individuals becoming
overburdened, leading to less self-management, greater in-
equalities, reduced access to services and poorer health and
well-being [8].
Self-management can empower cancer patients, increase
their confidence to manage problems associated with the
disease and its treatment and enhance quality of life [9, 10].
Foster and Fenlon [11] have set out a framework for recovery
of health and well-being in cancer survivorship which has
self-management and support for self-management as essen-
tial components. One element of the framework is cancer-
related self-efficacy; belief that one can successfully execute
behaviour required to produce expected outcome [12] in rela-
tion to consequences of cancer and its treatment. An adapted
version of the framework is illustrated in Fig. 1 to reflect
elements assessed in this study and demonstrating that the
focus of the study is on the factors predicted to be associated
with cancer-related self-efficacy. Higher self-efficacy has been
associated with a greater effort and persistence to cope with
obstacles [13] and enhanced well-being [14]. In people affect-
ed by cancer, a high degree of self-efficacy is associated with
increased self-care behaviours and decreased physical and
psychological symptoms [15]. Self-efficacy is likely to change
according to the task to be self-managed and is subject to
change [16, 17]. It has therefore become the target of many
self-management interventions [10]. Self-efficacy is not a
general trait and therefore a person cannot be described as
having high self-efficacy or low self-efficacy in all situations.
Rather, individuals have beliefs about their ability to carry out
tasks and these will vary according to the context and the
nature of the task. For example, someone may have high self-
efficacy in the workplace but low self-efficacy in relation to
exercise. Going further, someone who reports high self-
efficacy in the work place may have quite different self-
efficacy beliefs when work-related self-efficacy is examined
in more detail e.g. high self-efficacy for managing a team but
low self-efficacy for delivering a pitch to an audience. For
this reason, we have explored cancer-related self-efficacy
generally and then looked at different aspects of this to
understand areas where cancer survivors may have lower
self-efficacy to inform targeted intervention.
Little is known about cancer survivors’ cancer-related self-
efficacy and how problems are managed in the year following
treatment. This study set out to address this gap. Variables
were assessed that were expected to be associated with
self-efficacy: cancer and treatment related factors, socio-
demographic factors, quality of life, well-being, illness per-
ceptions, depression and social support [11]. Our hypotheses
were as follows:
1. Cancer-related self-efficacy will be influenced by socio-
demographic and clinical variables
2. Cancer-related self-efficacy will be positively associated
with well-being
3. Cancer-related self-efficacy will be negatively associated
with depression
4. Cancer-related self-efficacy will be negatively associated
with a more threatening perception of illness
5. Cancer-related self-efficacy will be positively associated
with social support
The purpose of the study was to identify who is most likely
to need support to self-manage cancer-related problems in the
year following primary treatment as indicated by lower self-
efficacy.
Methods
Design
This was a cross-sectional, online survey of adults who had
completed primary cancer treatment in the past year.
Participants
Eligible participants were as follows: ≥18 years; able to com-
plete the survey online in English; had completed primary
cancer treatment in the past 12 months; and were resident in
the UK. A sample size calculation was performed based on
expected variations in the Self-Efficacy forManaging Chronic
Disease Scale [18]. Previous studies using this measure have
indicated wide variations in self-efficacy scores [19, 20],
therefore, the calculation allowed for a 40 % difference
between scores; assumed a statistical significance level of
0.05; and a test with 85 % power, giving a required sample
size of 170.
Procedure
Ethical approval was granted by the University (REF: FoHS-
ETHICS-2011-051). The survey was created and managed
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using iSurvey [21]. Recruitment took place August–December
2011. The survey was advertised and linked to 35 charity
websites (including social media links), University website,
staff bulletins and posters in 260 libraries. Twitter and
Facebook accounts were created. Advertisements directed
individuals to the study website. Before completing the survey,
participants confirmed they had read the Patient Information
Sheet and met the inclusion criteria.
Measures
Validated measures, previously used in cancer populations and
informed by our recovery framework were included [11]. Par-
ticipants provided socio-demographic data and reported health
service use.
Primary outcome Self-Efficacy forManaging Chronic Disease
Scale was used [18] to measure self-efficacy in people with
chronic conditions and has been used with cancer patients
[22]. Respondents rate their confidence to perform six self-
management behaviours (1=‘not at all confident’ to 10=‘totally
confident’). A mean score is calculated (range 1 to 10). A high
score indicates high self-efficacy. We added five cancer-specific
self-management behaviours using the same rating scale and
calculated a mean score (range 1–10). The new Cancer Survi-
vors Self-efficacy Scale of 11 items was tested using non-
parametric, item-response theory (Mokken Scale analysis)
[23]. The full set of 11 items formed a strongly homogenous,
unidimensional scale of self-efficacy (H=0.54) with excellent
reliability (Alpha=0.92). We report the mean scale score and
also look at individual items to understand the range of self-
efficacy beliefs for different aspects of cancer-related self-
efficacy.
Health and well-being The Quality of Life in Adult Cancer
Survivors scale (QLACS) has been validated with long-term
cancer survivors [24]. The scale consists of 12 domains
(generic and cancer-specific). Respondents indicate the
frequency with which they experienced each quality of
life issue in the last 2 weeks (1=‘never’ to 7=‘always’).
Each domain is scored (range 4–28). Higher scores represent
poorer quality of life.
The Personal Wellbeing Index (PWI-A) measures sub-
jective quality of life amongst adults. Respondents indicate
their global satisfaction with life and satisfaction with eight
different aspects of their life (0=‘completely dissatisfied’ to
10=‘completely satisfied’) [25]. A mean score is calculated
and converted into a percentage. A higher value indicates
greater sense of well-being. The PWI has been used to
assess quality of life in people with spinal cord injury [26],
older people [27] and random samples, with good validity and
reliability [28].
Personal factors The Brief Illness Perception Questionnaire
(Brief IPQ) is an eight-item scale assessing cognitive and
emotional representations of illness [29]. Each item is scored
on a scale of 0 to 10 (e.g. 0=‘no affect at all’ to 10=‘severely
affects my life’). A total score (after appropriate reverse
scoring; range 0 to 80) represents the degree to which the
illness is perceived as threatening or benign (Broadbent,
personal communication). Higher scores reflect a more
threatening view of illness. The instrument has been used
with people with cancer [30].
The Center for Epidemiologic Studies Depression Scale
(CES-D) assesses how often (0=‘rarely or none of the time’ to
3=‘all of the time’) participants experienced a range of symp-
toms in the past week and yields a total score (after appropriate
reverse scoring; range 0 to 60) [31]. A higher score indicates
more frequent depressive symptoms. A score ≥16 suggests
psychological distress. A higher clinical cut-off of ≥20 or 27
has been suggested for cancer patients; although specificity
may be reduced i.e. the number of people who are incorrectly
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identified as NOT having minor or major depression is higher
[32]. The CES-D has been established as reliable and valid for
measuring depressive symptoms in people with cancer [33].
Environmental factors The Medical Outcomes Study (MOS)
social support survey measures availability of social support
[34]. Respondents indicate how often different kinds of sup-
port are available to them (1=‘none of the time’ to 5=‘all of
the time’). There are 18 items in 4 subscales. A mean score is
calculated to produce an overall support index: a higher score
denotes a greater level of social support. To compare to
published means, scale scores were transformed to a 0–100
scale. This survey has been tested for validity and reliability
with cancer survivors [35].
Analyses
The level of missing data was extremely low. In cases where
data contributing to a validated measure were missing, the
instructions given by the authors of the measure for the treat-
ment of missing data were followed. Where no explicit instruc-
tions for missing data were given, measures based on the sum
of scores were not calculated if any items were missing and
measures based on a mean score were not calculated if there
were more than two items missing. Independent t tests, one-
way analyses of variance, Pearson and Spearman rank correla-
tions were performed to establish relationships between self-
efficacy and other variables. A backward elimination method
was used to perform linear regression analysis. Separate regres-
sions, with variables grouped according to the conceptual
framework and significant variables, were carried forward to
a final analysis. Collinearity diagnostics for all regression
models were run; a threshold of <0.1 for tolerance and >10
for the variance inflation factor was observed [36, 37].
Results
Two hundred thirty-four people completed the online survey.
One hundred eighty-two met the eligibility criteria and were
included in the analyses; 52 were ineligible (50 had not
completed treatment in past 12 months; 2 entered no data).
Characteristics of the sample
Socio-demographic and clinical data are presented in Table 1.
Mean time since treatment completion was 5.36 months. Most
respondents were female and described themselves as White
British. Ages ranged from 23 to 79 years. Respondents reported
21 different cancer diagnoses. The largest single group were
breast cancer survivors. One hundred seventy-seven (97 %)
respondents had received surgery, radiotherapy or chemotherapy
(or a combination). The most common treatment was surgery.
Comorbidities, such as asthma, diabetes and arthritis, were
reported by almost 40 % of respondents.
Health service use
All respondents had used health services at least once in the
past year: 174 (96 %) had seen a General Practitioner, 159
Table 1 Socio-demographic and clinical characteristics of respondents
Characteristic Number or mean (%)
n=182
Age 50 years (SD 9.505)
Gender Female: 147 (80.8)
Male: 35 (19.2)
Ethnicity
White British 166 (91.2)
White Irish 5 (2.7)
Other White background 9 (4.9)
White and Hispanic 1 (0.5)
Other mixed background 1 (0.5)
Highest educational attainment
Higher degree 33 (18.1)
Degree 56 (30.8)
A levels or equivalent 46 (19.8)
GCSE/O levels or equivalent 32 (23.1)
No formal qualifications 15 (8.2)
Domestic status
Married 103 (56.6)
Divorced/separated 27 (14.8)
Living with partner 22 (12.1)
Single 25 (13.7)
Widowed 3 (1.6)
Missing 2
Employment status
Employed 132 (72.5)
Not employed 50 (27.5)
Months since completion of treatment 5.36 (SD 3.848)
Treatment received in past 12 months
Surgery 119 (65.4)
Radiotherapy 102 (56.0)
Chemotherapy 99 (54.4)
Cancer type
Breast 82 (45.1)
Urological 23 (12.6)
Gynaecological 21 (11.5)
Gastrointestinal 18 (10.0)
Haematological 17 (9.3)
Other 13 (7.1)
Missing 8
Comorbidities reported 70 (38.5)
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(87 %) an oncologist, 153 (84 %) a cancer nurse and 149
(82 %) a surgeon. One hundred thirty-one (72 %) had stayed
overnight in hospital.
Self-efficacy to manage consequences of cancer
and its treatment
The mean score on the Cancer Survivors Self-Efficacy scale
was 6.87 (SD 1.79)1 (range: 1–10; higher score=greater self-
efficacy). The mean score for each individual item was calcu-
lated to highlight variations in self-efficacy across tasks. Self-
efficacy to manage fatigue was lowest and self-efficacy to
access information about cancer and treatment effects was
highest as shown in Fig. 2.
Hypothesis 1 Cancer-related self-efficacy will be influenced
by the socio-demographic and clinical variables
Some socio-demographic variables were associated with
self-efficacy. Male respondents reported higher self-efficacy
than females (t=2.595, p<0.05); those who believed their
cancer affected the amount or kind of work that they could
do were more likely to have lower self-efficacy than those
who did not (t=5.857, p<0.01); home owners or those renting
from a private landlord reported higher self-efficacy than
those renting from a Council or Housing Association or living
in temporary or other accommodation (t=−2.608, p<0.05).
Contrary to Hypothesis 1, cancer-related self-efficacy did not
differ significantly by age, marital, or employment status; or
clinical characteristics: type of cancer or treatment, time since
diagnosis or comorbidities.
Health and well-being
Hypothesis 2 Cancer-related self-efficacy will be positively
associated with well-being
The Generic Summary Score for QLACS was 109.20 (SD
22.68) and the Cancer Specific Summary was 57.20 (SD
19.57). QLACS domain scores ranged from 10.97 (Distress-
Family), the least frequently experienced problem, to 18.28
(Energy/Fatigue), the most frequently experienced problem
(Table 2). 67 % of respondents reported that they frequently,
very often or always experienced problems with fatigue
(score ≥5). In terms of concerns about recurrence (scores≥5;
frequently, very often or always), 50 % of respondents reported
worrying about dying from cancer, 67 % reported worry about
recurrence, 53 % reported worrying that pains were a sign of
recurrence and 47 % reported being preoccupied with concerns
about cancer. Mean PWI was 58.7 (SD 21.8) where a lower
score indicates poorer well-being. The normative range for
Western populations is 70–80 [36]. There were strong correla-
tions between self-efficacy and QLACS (GSS r=−0.65,
p<0.001; CSS r=−0.52, p<0.001) and PWI (r=0.746,
p<0.001). Better health and well-being was associated with
higher self-efficacy across all domains (p<0.001) confirming
Hypothesis 2.
Personal factors
Hypothesis 3 Cancer-related self-efficacy will be negatively
associated with depression
Hypothesis 4 Cancer-related self-efficacy will be negatively
associated with a more threatening perception
of illness
Mean CES-D was 21.04 (SD 12.44; range 0–60). Of the
patients included, 62 % had scores of ≥16, suggesting clinically
significant psychological distress; 49 % had scores ≥20 and
32% scores ≥27. It is unclear what an appropriate cut-off should
be, thereforewe examined individual items. Ten percent reported
that they ‘felt depressed’ ‘all of the time’, 20 % that they ‘felt
depressed’ ‘occasionally/moderate amount of the time’. Twenty-
five percent reported that they ‘rarely’ felt hopeful for the future.
Sixty-six percent of respondents reported restless sleep (‘all of
the time’—40 %; or ‘occasionally/moderate amount of the
time’—26 %) which may explain the high total CES-D
scores. Higher CES-D scores were associated with lower levels
of self-efficacy (r=−0.75, p<0.001) confirming Hypothesis 3.
Mean Brief IPQwas 39.93 (SD 13.70; range 0–80) where a
higher score indicates more threatening perception of the
illness. A more threatening perception of illness was associ-
ated with poorer self-efficacy (r=−0.41, p<0.001) confirming
Hypothesis 4.
Environmental factors
Hypothesis 5 Cancer-related self-efficacy will be positively
associated with social support
The mean overall support score was 67.07 (SD 27.6). Least
support was reported for emotional/informational support and
most support for positive social interaction. However, there is
wide variation in the scores for overall social support and the
sub-scale scores. Most participants reported adequate social
support (score≥4; most to all of the time) in terms of positive
social interaction (65.3 %), affectionate (69 %) and tangible
(53.2 %) support. Only 40 % reported adequate emotional/
informational support (e.g. someone to confide in, someone to
give good advice and information). Higher levels of social
support were associated with higher self-efficacy (r=0.53,
p<0.001) confirming Hypothesis 5.
1 Mean score for the six items of the original Self-Efficacy for Managing
Chronic Disease 6-item Scale was 6.34 (SD 2.05)
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Regression analysis
We conducted a backward, stepwise regression analysis to
investigate relationships between self-efficacy and the vari-
ables proposed in the selected elements of our conceptual
framework as illustrated in Fig. 1 [11]. The final model for
self-efficacy (Table 3) included the following: QLACS pain
sub-scale, PWI, CES-D, accommodation (owner occupier/
renting privately versus not), gender, illness perception and
social support. The model accounts for 76% of the variance in
self-efficacy. Variables most strongly associated with a low
self-efficacy score were the following: higher level of pain;
lower subjective sense of well-being; higher depression; not
living in owner-occupied or privately rented accommodation;
being female; having a more threatening perception of cancer;
having a lower level of social support.
Discussion
Compared to studies of cancer survivors, participants in this
online survey were doing less well on almost all quality of life
dimensions [24]. However, participants in this study had
completed their primary treatment more recently (in the past
12 months vs ≥5 years ago). They also reported higher rates of
depression, as measured by the CES-D, than reported else-
where, for example, in head and neck cancer patients up to
6 weeks post radiotherapy [32] and breast cancer survivors
1–5 years post diagnosis [38]. The numbers remained high
for clinically significant depression when we raised the
clinical cut-off as suggested in the literature for individuals
with cancer [32]. Respondents reported greater frequency
of fatigue (67 % reporting frequently to always) than
previously reported amongst cancer survivors [5]. The high
scores may in part be explained by high fatigue levels and
problems with sleep reported by the participants rather
than their perceptions of ‘feeling depressed’ so this needs
to be interpreted with caution. In relation to personal well-
being, participants were doing less well than the general
population [28]. Participants in this study had comparable
social support scores to others with chronic conditions [34].
There was wide variation in self-reported social support in this
sample across the four domains of social support.
Table 2 Quality of life, illness perceptions, depressive symptoms and
perceived social support
Measure n Mean (SD)
Quality of Life in Adult Cancer Survivors
(scores: 4–28; high score=more problems)
Energy/Fatigue 179 18.28 (4.94)
Distress-Recurrence 182 18.19 (6.53)
Positive feelings 181 16.94 (5.13)
Benefits 182 16.63 (6.12)
Sexual Problems 175 16.26 (6.64)
Pain 181 15.05 (5.79)
Negative feelings 179 15.02 (5.14)
Cognitive Problems 179 14.59 (5.68)
Appearance 180 14.28 (6.93)
Financial Problems 178 13.67 (7.46)
Social Avoidance 175 13.53 (6.44)
Distress-Family 182 10.97 (5.45)
QLACS Generic Summary Score
(GSS range 59–161)
168 109.20 (22.68)
QLACS Cancer Specific Summary
(CSS range 18–101)
176 57.20 (19.57)
Personal Wellbeing Index
(scores: 0–100; high score=better wellbeing)
181 58.7 (21.8)
Brief Illness Perception Questionnaire
(scores: 0–80; high score=more threatening
perception)
179 39.93 (13.70)
MOS social support survey (scores: 0–100;
high score=more support)
Overall support index 174 67.06 (27.6)
Emotional/informational support 179 61.10 (31.19)
Tangible support 178 66.92 (33.49)
Affectionate support 177 75.99 (32.06)
Positive social interaction 179 73.09 (29.51)
5.83
SD 2.56
5.97
SD 2.55
6.08
SD 2.47
6.41
SD 2.55
6.55
SD 2.38
6.84
SD 2.23
6.89
SD 2.68
6.89
SD 2.20
7.92
SD 2.25
7.97
SD 2.45
8.22
SD 2.00
1
2
3
4
5
6
7
8
9
10
Self-efficacy to manage (Mean)Fig. 2 Self-efficacy to manage
consequences of cancer and its
treatment. Measured by the
Cancer Survivors Self-Efficacy
Scale (high score denotes higher
self-efficacy)
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Confidence to self-manage problems faced as a conse-
quence of cancer and its treatment varied widely in the
12 months following treatment. Our results are comparable
with a study of patients with chronic conditions attending
general practices in Germany [39]. Given the higher than
expected level of unmet need in our group—particularly in
relation to fatigue—it is important to highlight that partici-
pants reported low self-efficacy to manage the consequences
of fatigue in their everyday lives. Lowest self-efficacy scores
were for managing fatigue, emotional distress and health
problems.
Relatively high self-efficacy scores for accessing informa-
tion and support suggests a sample comfortable with accessing
information and engaging with support services. This may
reflect the relatively high levels of education the sample
reported, compared to the general population, as well as a
relatively high level of computer literacy implied by partici-
pating in the online survey. We have established a clinical
cohort of colorectal cancer patients and plan to explore these
issues with the cohort participants [40].
As indicated above, levels of self-efficacy varied according
to the task, supporting the view that self-efficacy is domain
specific [16, 17]. This underlines the importance of consider-
ing variation in an individual’s self-efficacy for self-managing
different problems associated with cancer and its treatment,
rather than viewing individuals as having confidence or not in
a general sense. Domain-specific cancer-related self-efficacy
measures are likely to be valuable in helping to identify cancer
survivors who lack self-efficacy for particular tasks or behav-
iours. Identification of low self-efficacy in specific behaviours
could facilitate targeted support for cancer survivors to better
self-manage consequences of cancer and treatment.
Those most at risk of overall low self-efficacy to manage
the consequences of their cancer and its treatment were
women, those experiencing higher levels of pain, depres-
sion, lower wellbeing scores, who did not own their own
home or live in privately rented accommodation, had low
levels of social support and a more threatening perception
of their cancer. Our conceptual model of recovery [11]
predicts which factors will impact an individual’s cancer-
related self-efficacy. In the model, subjective health and
well-being, environmental factors and personal factors influ-
ence cancer-related self-efficacy which, in turn, has an effect on
an individual’s choice of self-management strategies. These
study findings lend support to this model, although as these
data are from a cross-sectional survey, we cannot determine
causality. Our results, therefore, highlight the possibility of
targeting support to cancer survivors who are likely to have
lower self-efficacy to manage cancer-related consequences so
that they can be supported to self-manage.
Some limitations of this study should be considered when
interpreting the findings. Analysis of respondents’ socio-
demographic characteristics suggests that these cancer survi-
vors were not representative of the wider population of people
living with and beyond cancer. Those taking part in this study
were self-selected, younger and more likely to be female,
White British and achieved a higher level of education than
might be expected in a representative sample of cancer survi-
vors [41, 42]. In addition, the cancer survivors who responded
to this survey reported higher levels of psychological distress
than might have been expected. In a cancer population, about
20%would be expected to have clinically significant levels of
distress [33].We have established a prospective clinical cohort
of colorectal cancer survivors and will explore cancer-related
self-efficacy further in this group [40].
Conclusions
This study demonstrates that cancer survivors have varying
levels of self-efficacy according to different tasks to be man-
aged in the year following treatment. This has implications for
how self-efficacy is assessed to identify specific areas of low
confidence amongst patients living with cancer or treatment
related problems. The regression model indicates a number of
Table 3 Regression analysis of
factors associated with self-
efficacy (n=182)
R2 =0.758
*p<0.05; **p<0.01
Model Unstandardised
Coefficients
Standardised
Coefficients
95 % Confidence
interval for B
B Standard error Beta
Constant 7.561 0.614 6.348 8.773
Pain (QLACS) −0.052 0.015 −0.167** −0.082 −0.022
Personal wellbeing (PWI) 0.199 0.052 0.240** 0.096 0.301
Depression (CES-D) −0.029 0.009 −0.200** −0.047 −0.011
Housing 0.414 0.206 0.081* 0.007 0.821
Gender −0.415 0.188 −0.090* −0.785 −0.044
Illness perception (IPQ) −0.038 0.008 −0.284** −0.053 −0.022
Social support (MOS) 0.282 0.081 0.171** 0.123 0.442
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factors which may help identify patients at risk of having low
confidence to manage problems associated with cancer.
Given that growing numbers of cancer survivors will be
expected to self-manage their aftercare, it is important to
assess confidence to self-manage the different elements of
aftercare, for example, managing consequences of cancer
and its treatment; accessing information and support as re-
quired; identifying signs and symptoms of possible disease
progression; and making lifestyle changes as appropriate. This
has implications for targeting support designed to improve
self-efficacy.
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